Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Invest New Drugs. 2015 Mar 18;33(3):555–563. doi: 10.1007/s10637-015-0228-4

Table 3.

Median survival time of F98 glioma bearing Fischer rats

Treatmenta MSTd (days) MeSTc (days) Range (days) P valuef
5% Dextrose 22.9 ± 2.1 23.5 19–25
5% Dextrose + 15 Gyb 31.8 ± 5.2 30.0 26–35 P=0.0002
7.5 μg Cisplatinc 36.1 ± 6.6 35.5 25–46 P<0.0001
7.5 μg Cisplatin + 15 Gy 39.3 ± 4.5 39.0 32–45 P=0.0002
7.5 μgLipoplatin 27.0 ± 2.0 26.5 25–31 P=0.0004
25 μg Carboplatin 40.9 ± 6.0 38.5 31–47 P<0.0001
25 μg Carboplatin + 15 Gy 53.1 ± 9.6 54.0 39–65 P<0.0001
a

Injection volume = 10 μL.

b

Radiotherapy was delivered 24 h after chemotherapy.

c

Drugs were tested at their respective MTD.

d

Mean Survival Time

e

Median Survival Time

f

Compared to 5% Dextrose

HHS Vulnerability Disclosure